UPDATE: Wedbush Downgrades Synageva BioPharma on Valuation
October 07, 2013 at 10:55 AM EDT
In a report published Monday, Wedbush analyst David M. Nierengarten downgraded the rating on Synageva BioPharma Corp. (NASDAQ: GEVA ) from Outperform to Neutral, but raised the price target from $55.00 to $67.00. In the report, Wedbush noted, “We are downgrading shares of Synageva due to valuation. We continue to
